| Recently, Johnson & Johnson announced that it has successfully completed the acquisition of Ambrx Biopharma, Inc. Ambrx Biopharma is a clinical-stage biopharmaceutical company with a proprietary synthetic biology technology platform for designing and developing next-generation ADCs. The acquisition was completed in an all-cash merger transaction with a total equity value of approximately $2 billion (approximately 14.3 billion RMB at the time), and a net amount of $1.9 billion after deducting estimated acquired cash, as announced on January 8, 2024. This transaction will be considered a business combination. "We are thrilled that Ambrx's talented scientific team and their proprietary ADC platform are joining Johnson & Johnson. We look forward to continuing the development of ARX517, which has the potential to become the first best-in-class PSMA-targeted ADC for the treatment of metastatic castration-resistant prostate cancer," said Dr. Yusri Elsayed, Global Head of Oncology Therapeutic Area at Johnson & Johnson Innovative Medicine. "This significant opportunity lays the foundation for us to advance the next generation of ADCs, aiming to deliver differentiated treatments for solid tumors to improve patients' lives."
In 2003, Ambrx spun off from the Scripps Research Institute and has since developed into a clinical-stage company focused on biopharmaceuticals. The company innovatively developed the Expanded Genetic Code technology platform, which enables the incorporation of synthetic amino acids (SAA) into proteins at specific positions using common cell lines. SAA allows for site-specificity, homogeneity, and stability in engineered precision biologics, addressing limitations of traditional conjugation technologies.The engineered precision biologics (EPBs) produced by Ambrx Biopharma possess precise, stable, and homogeneous properties. Therefore, ADC drugs made from them exhibit enhanced safety and efficacy while significantly reducing chemotherapy-related side effects.Currently, Ambrx has three core projects in the clinical stage, with the fastest-progressing being the HER2 receptor-targeted candidate drug ARX788. In addition, the company is actively advancing other preclinical projects and therapeutic pipelines targeting various diseases., including the proprietary ADC ARX517 targeting prostate-specific membrane antigen (PSMA) and the proprietary ADC ARX788 targeting HER2.TargetTo PSMAARX517 has been granted Fast Track designation by the FDA for the treatment of metastatic castration-resistant prostate cancer (mCRPC).According to AmbrxLast YearAccording to the published clinical data of ARX517, the drug demonstrated consistent and promising anticancer activity in heavily pretreated patients at doses of 2.0–2.88 mg/kg, with 52% of the patients experiencing a prostate-specific antigen (PSA) reduction of more than 50%.And no serious adverse events or dose-limiting toxicities related to the drug were observed in any of the cohorts.▲ Ambrx Oncology PipelineFigure(Source: Ambrx)This acquisition presents a unique opportunity for Johnson & Johnson to design, develop, and commercialize targeted oncology therapeutics. Ambrx's proprietary ADC technology combines the advantages of highly specific targeting monoclonal antibodies with the safe linkage of potent chemotherapeutic drug payloads, enabling targeted and efficient elimination of cancer cells while avoiding common side effects typically associated with chemotherapy.
"The Ambrx team has developed a promising pipeline of drug candidates and an ADC platform, which will significantly complement and align with our oncology innovation strategy," said Biljana Naumovic, Global Vice President of Oncology at Johnson & Johnson Innovative Medicine. "ADCs are transforming the treatment paradigm for solid tumors by leveraging antibody-antigen interactions to deliver cytotoxic payloads directly into tumor cells. This acquisition underscores our ambition to deliver enhanced, precision biologics to revolutionize cancer treatment, including prostate cancer." | 
